The Food and Drug Administration’s Tobacco Products Scientific Advisory Committee (TPSAC) concluded milder health warnings suggested by Swedish Match in its reduced-risk application for snus do not fully convey the product’s health risks, the New York Times said.

TPSAC recommendations are not binding, however approval of Swedish Match’s application, the first to be considered by FDA under guidelines for modified risk tobacco products, would be difficult following the TPSAC meeting, the newspaper said. FDA has until June to rule on the application, which would apply to Swedish Match products sold in the US.
TPSAC met for two days on the application. Members of the outside advisory panel of experts said more studies were needed to be certain milder warnings than for standard tobacco products are justified, the Times said.